 CAMBRIDGE, Mass.--BUSINESS WIRE--- VBIV--VBI Vaccines Inc. Nasdaq: VBIV VBI, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the VBI leadership team will discuss the recent news and strategic outlook for the Companys hepatitis B HBV portfolio with covering analyst, Steven Seedhouse, Ph.D., from Raymond James Associates, Inc. during a fireside chat at 11:00 AM ET on Tuesday, December 8 